NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Thursday reported a loss of $14.9 million in its third quarter.
The New York-based company said it had a loss of 34 cents per share.
The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 43 cents per share.
The biopharmaceutical company posted revenue of $13.3 million in the period, falling short of Street forecasts. Five analysts surveyed by Zacks expected $13.4 million.
Stemline Therapeutics shares have risen almost 10% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $10.44, a fall of 30% in the last 12 months.